Cryo-EM structure of human mTOR complex 2
- PMID: 29567957
- PMCID: PMC5951902
- DOI: 10.1038/s41422-018-0029-3
Cryo-EM structure of human mTOR complex 2
Abstract
Mechanistic target of rapamycin (mTOR) complex 2 (mTORC2) plays an essential role in regulating cell proliferation through phosphorylating AGC protein kinase family members, including AKT, PKC and SGK1. The functional core complex consists of mTOR, mLST8, and two mTORC2-specific components, Rictor and mSin1. Here we investigated the intermolecular interactions within mTORC2 complex and determined its cryo-electron microscopy structure at 4.9 Å resolution. The structure reveals a hollow rhombohedral fold with a 2-fold symmetry. The dimerized mTOR serves as a scaffold for the complex assembly. The N-terminal half of Rictor is composed of helical repeat clusters and binds to mTOR through multiple contacts. mSin1 is located close to the FRB domain and catalytic cavity of mTOR. Rictor and mSin1 together generate steric hindrance to inhibit binding of FKBP12-rapamycin to mTOR, revealing the mechanism for rapamycin insensitivity of mTORC2. The mTOR dimer in mTORC2 shows more compact conformation than that of mTORC1 (rapamycin sensitive), which might result from the interaction between mTOR and Rictor-mSin1. Structural comparison shows that binding of Rictor and Raptor (mTORC1-specific component) to mTOR is mutually exclusive. Our study provides a basis for understanding the assembly of mTORC2 and a framework to further characterize the regulatory mechanism of mTORC2 pathway.
Conflict of interest statement
The authors declare no competing interests.
Figures







Similar articles
-
Interactions between mTORC2 core subunits Rictor and mSin1 dictate selective and context-dependent phosphorylation of substrate kinases SGK1 and Akt.J Biol Chem. 2022 Sep;298(9):102288. doi: 10.1016/j.jbc.2022.102288. Epub 2022 Aug 1. J Biol Chem. 2022. PMID: 35926713 Free PMC article.
-
Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.Oncotarget. 2015 Feb 28;6(6):4286-98. doi: 10.18632/oncotarget.3006. Oncotarget. 2015. PMID: 25738366 Free PMC article.
-
Identification of rictor as a novel substrate of Polo-like kinase 1.Cell Cycle. 2015;14(5):755-60. doi: 10.1080/15384101.2014.998050. Cell Cycle. 2015. PMID: 25714006 Free PMC article.
-
Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.Curr Cancer Drug Targets. 2016;16(4):288-304. doi: 10.2174/1568009616666151113120830. Curr Cancer Drug Targets. 2016. PMID: 26563881 Review.
-
Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.Adv Biol Regul. 2017 May;64:39-48. doi: 10.1016/j.jbior.2016.12.001. Epub 2017 Jan 4. Adv Biol Regul. 2017. PMID: 28189457 Review.
Cited by
-
Amino acid-dependent control of mTORC1 signaling: a variety of regulatory modes.J Biomed Sci. 2020 Aug 17;27(1):87. doi: 10.1186/s12929-020-00679-2. J Biomed Sci. 2020. PMID: 32799865 Free PMC article. Review.
-
mTOR as a central hub of nutrient signalling and cell growth.Nat Cell Biol. 2019 Jan;21(1):63-71. doi: 10.1038/s41556-018-0205-1. Epub 2019 Jan 2. Nat Cell Biol. 2019. PMID: 30602761 Review.
-
mTOR: A Cellular Regulator Interface in Health and Disease.Cells. 2019 Jan 2;8(1):18. doi: 10.3390/cells8010018. Cells. 2019. PMID: 30609721 Free PMC article. Review.
-
Cluster Analysis of Endogenous HER2 and HER3 Receptors in SKBR3 Cells.Bio Protoc. 2018 Dec 5;8(23):e3096. doi: 10.21769/BioProtoc.3096. eCollection 2018 Dec 5. Bio Protoc. 2018. PMID: 34532543 Free PMC article.
-
m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition.Cancer Lett. 2023 May 28;562:216178. doi: 10.1016/j.canlet.2023.216178. Epub 2023 Apr 14. Cancer Lett. 2023. PMID: 37061119 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous